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OBJECTIVE—Endothelial progenitor cells (EPCs) are decreased
in number and function in type 2 diabetes. Mechanisms by which
this dysfunction occurs are largely unknown. We tested the
hypothesis that a chronic inﬂammatory environment leads to
insulin signaling defects in EPCs and thereby reduces their
survival. Modifying EPCs by a knockdown of nuclear factor-kB
(NF-kB) can reverse the insulin signaling defects, improve EPC
survival, and decrease neointimal hyperplasia in Zucker fatty
rats postangioplasty.
RESEARCH DESIGN AND METHODS—EPCs from Zucker
fatty insulin-resistant rats were cultured and exposed to tumor
necrosis factor-a (TNF-a). Insulin signaling defects and apoptosis
were measured in the presence and absence of an NF-kB inhib-
itor, BAY11. Then, EPCs were modiﬁed by a knockdown of
NF-kB (RelA) and exposed to TNF-a. For in vivo experiments,
Zucker fatty rats were given modiﬁed EPCs post–carotid angio-
plasty. Tracking of EPCs was done at various time points, and
neointimal hyperplasia was measured 3 weeks later.
RESULTS—Insulin signaling as measured by the phosphorylated–
to–total AKT ratio was reduced by 56% in EPCs exposed to TNF-a.
Apoptosis was increased by 71%. These defects were reversed by
pretreatment with an NF-kB inhibitor, BAY11. Modiﬁed EPCs
exposed to TNF-a showed a lesser reduction (RelA 20%) in
insulin-stimulated AKT phosphorylation versus a 55% reduction
in unmodiﬁed EPCs. Apoptosis was 41% decreased for RelA
knockdown EPCs. Noeintimal hyperplasia postangioplasty was
signiﬁcantly less in rats receiving modiﬁed EPCs than in con-
trols (intima-to-media ratio 0.58 vs. 1.62).
CONCLUSIONS—In conclusion, we have shown that insulin
signaling and EPC survival is impaired in Zucker fatty insulin
resistant rats. For the ﬁrst time, we have shown that this defect can
be signiﬁcantly ameliorated by a knockdown of NF-kBa n dt h a t
these EPCs given to Zucker fatty rats decrease neointimal hyper-
plasia post–carotid angioplasty. Diabetes 60:1286–1294, 2011
D
iabetes is at epidemic proportions in the U.S.
Insulin resistance without overt diabetes is
even more prevalent, with over 25% of the
population reported to have several components
of the insulin resistance syndrome. The insulin resistance
syndrome is associated with hyperinsulinemia, obesity,
dyslipoproteinemia, hypertension, and abnormalities of
several nontraditional risk factors such as endothelial
dysfunction, abnormal ﬁbrinolysis, and inﬂammation (1,2).
Insulin resistance, even in the absence of other traditional
cardiovascular risk factors, is associated with endothelial
dysfunction in the peripheral and coronary arteries (3). A
common complication in patients with diabetes and insulin
resistance is restenosis after angioplasty and stent place-
ment. Studies have shown that insulin levels are the best
predictor of neointimal proliferation post–angioplasty and
stent placement even in patients without diabetes (4,5).
Growing evidence over recent years supports a potential
role for cytokine-associated, subacute inﬂammation in the
pathogenesis of insulin resistance and type 2 diabetes (6).
Insulin resistance (with or without hyperglycemia), dys-
lipidemia, and hypertension all increase risk for athero-
sclerosis, which is itself increasingly thought to be a disease
of chronic subacute inﬂammation (7,8). These interrela-
tionships suggest that inﬂammation may be the basis of a
“common soil” involved in the pathogenesis of both type
2 diabetes and atherosclerosis.
Recent studies suggest that a state of chronic, subacute
inﬂammation—speciﬁcally mediated by nuclear factor-kB
(NF-kB), c-jun NH2-terminal kinase, or P38 mitogen-activated
protein kinase (MAPK) pathways—might both be involved
in the pathogenesis of insulin resistance and provide new
targets for its reversal (9–15). Inﬂammatory cytokines like
tumor necrosis factor-a (TNF-a) have been shown to re-
duce insulin signaling by decreasing insulin receptor sub-
strate (IRS)-1 tyrosine phosphorylation, phosphatidylinositol
3-kinase (PI3K), and AKT activity. These alterations in in-
sulin signaling can lead to increased apoptosis and impaired
wound healing.
Endothelial progenitor cells (EPCs) are circulating cells
with the ability to differentiate into mature endothelium
and take part in endothelial repair and maintenance. A
decrease in the number and function of EPCs has been
associated with a large number of risk factors for athero-
sclerosis (16,17). Several studies show that circulating
EPCs are decreased in patients with diabetes (18,19).
EPCs from diabetic patients display functional impair-
ments, such as reduced proliferation, adhesion, migration,
and incorporation into tubular structures (20,21). De-
creased number of circulating EPCs has been reported in
patients with the insulin resistance syndrome, negatively
correlating with homeostasis model assessment of insulin
resistance (22). Studies looking at the effects of EPC
dysfunction in diabetes on endothelial regrowth and neo-
intimal hyperplasia after vessel injury are very few. One
study showed that reendothelialization was signiﬁcantly
reduced in nude nondiabetic mice injected with EPCs from
diabetic mice when compared with mice injected with
normal EPCs (23,24). However, very little is known about
the mechanisms that might lead to the inability of EPCs in
an inﬂammatory, insulin-resistant environment, to induce
reendothelialization and decrease neointimal hyperplasia.
The inability of EPCs to respond adequately to insulin may
result in dysfunction in the setting of insulin-resistant
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ORIGINAL ARTICLEstates and ultimately lead to increased neointimal hyper-
plasia postangioplasty.
In this article, we test the hypothesis that cytokines
present in a chronic inﬂammatory environment lead to
insulin signaling defects in EPCs and thereby reduce their
survival. We also test the hypothesis that modifying EPCs
by a knockdown of NF-kB can reverse the insulin signaling
defects in EPCs and that an infusion of these modiﬁed
EPCs decreases neointimal hyperplasia postangioplasty in
a rat model of insulin resistance.
RESEARCH DESIGN AND METHODS
The Zucker fa/fa obese rat developed by Charles River Laboratory, Wilmington,
MA, is a nondiabetic model of insulin resistance. These rats have marked obe-
sity, hyperinsulinemia, insulin resistance, and mild hypertriglyceridemia. How-
ever, they are normotensive and normoglycemic. SD rats are normoglycemic
with no insulin resistance.
First set of experiments. In the ﬁrst set of experiments, EPCs from Zucker
fatty rats and normal SD rats (n = 6 each) were obtained. Dose-dependant
insulin stimulation of Akt phosphorylation (insulin signaling) was measured
in Zucker and SD rat EPCs to compare the level of insulin resistance
(Supplementary Fig. 1). Subsequently, the effect of TNF-a on insulin signaling
and apoptosis was ascertained. The inhibitor of NF-kB, Bay-11, was used to
determine whether these effects could be reversed in both Zucker and SD rats.
In another set of experiments, EPCs from Zucker fatty rats (n = 6) were
obtained and the effect of TNF-a on interleukin (IL)-8 secretion was assessed.
EPC culture and characterization. EPCs from Zucker fatty rats and SD rats
were obtained in the following manner. Blood (7–8 mL) from insulin-resistant
Zucker fa/fa obese or SD rats (14–15 weeks old) was obtained. Citrate-treated
blood was centrifuged and treated with erythrocyte lysis buffer (ammonium
acetate). Cells were counted and diluted to 5 3 10
6 cells/mL in sterile PBS with
5% BSA. Cells were then centrifuged to pellet cells. Primary antibodies
(CD133-PE, eBioscience; CD34-PE-Cy7, Santa Cruz; and CD45-Alexa Fluor
647, Biolegend) were added to the cells and incubated with anti-mouse com-
pensation beads (BD) for 30 min. Cells were then ﬁltered through a cell
strainer (BD Falcon). Cells were taken to the cell analysis facility and sorted
on FACSAria (Becton-Dickinson) for cells that positively label for CD45,
CD34, and CD133. Subsequently, cells were grown for 5 days on ﬁbronectin-
coated dishes in endothelial growth medium-2 (Lonza). Cells were then re-
identiﬁed by incubating 100 mL of cells with the primary antibodies, taken to
the cell-analysis facility, and resorted and analyzed by ﬂow cytometry to check
CD labeling after ex vivo expansion. Additionally, EPC characteristics were
demonstrated by tube formation assay. Filtration was carried out to prevent
cell clotting and microembolization.
Assessment of EPC IL-8 response to TNF-a. EPCs were serum starved for
10 h and then exposed to 10 ng/mL TNF-a for 12 h. Subsequently, media was
collected and the assays for IL-8 (R&D Systems) were performed using enzyme-
linked immunoassay (ELISA) kits per the manufacturer’sp r o t o c o l s .
Assessment of EPC insulin signaling and survival in the presence/
absence of TNF-a. EPCs, sorted as described above, were seeded onto
a poly-L-lysine–coated 96-well plate and allowed to attach. The media was
changed to starvation media (0.5% FBS in endothelial basal medium), and the
cells were starved for 10 h. The cells were then treated with 10 ng/mL TNF-a
and 3 mmol/L Bay11 for 12 h. Insulin (1 mmol/L) was then added for 1 h to
stimulate the insulin signaling pathway. The cells were then assayed according
to the directions of the cell-based ELISA (R&D Systems) for AKT and phos-
phorylated AKT (category no. KCB887). Brieﬂy, the cells were treated with
formaldehyde to ﬁx the cells and then washed. The cells were then treated
with quenching buffer, washed, treated with blocking buffer, and washed
again. Subsequently, primary antibodies for phosphophorylated and total AKT
were added and incubated overnight. The next day, the cells were washed and
incubated with the secondary antibodies. The cells were washed, and sub-
strate F1 was added. Later, substrate F2 was also added. The plate was read
using a ﬂuorescence plate reader at 600 nm (for phosphorylated AKT) and 450
nm (for total AKT). This was then expressed as a ratio.
EPC apoptosis. EPCs were sorted and prepared as described above. Cells
were serum starved for 10 h and then treated with 10 ng/mL TNF-a and 3 mmol/L
Bay11 for 12 h. The apoptosis assay was performed with Chemicon’s Caspase-3
Colorimetric Activity Assay kit for assaying the activity of caspases that recog-
nize the sequence Asp-Glu-Val-Asp (DEVD). After cleavage from the labeled
substrate DEVD-pNA, the free pNA was quantiﬁed using a microtiter plate
reader at 405 nm. We compared absorbance of pNA from apoptotic samples
with that of uninduced controls, determining the fold increases in caspase-3
activity.
Angiogenesis tube formation elongation assay. Wells were coated with
Extracellular Matrix gel (Category no. 10009964; Caymen Chemical Company)
and allowed to solidify. EPCs were added to the gel with or without activators
(25 or 50 mmol/L phorbol 12-myristate 13-acetate) or inhibitors (0.3 mmol/L;
JNJ-10198409). Cells were placed in a cell culture incubator. After several
days, calcein AM was added to the cells and the structure was captured using
an inverted ﬂuorescence microscope. Tube length was measured using anal-
ysis software. Results are shown in Supplementary Fig. 5.
Second set of experiments. EPCs from Zucker fatty rats (n = 6) were
obtained sorted, expanded ex vivo as described earlier, and modiﬁed by
suppressing NF-kB (RelA) with siRNA. The modiﬁed EPCs’ response to TNF-
a–induced IL-8 was assessed. The effect of TNF-a on insulin signaling and
apoptosis in these modiﬁed EPCs was also ascertained.
Effect of NF-kB suppression: siRNA transfection. EPCs were sorted and
cultured as described above. siRNA transfections were performed with Fugene
6 reagent according to the manufacturer’s protocol. All three control siRNA
(catalog no. 4611) and suppressor of cytokine signaling-3 or NF-kB siRNA
(catalog no. AM16708A) were purchased from Ambion (Austin, TX). Brieﬂy,
a 24-well plate with 40,000 cells/well was exposed to 2 mL transfecting agent
and siRNA at a concentration of 30 nmol/L for a period of 24 h. The medium
was changed, and cells were treated with TNF-a (10 ng/mL) for 12 h. In the last
hour, 10 nmol/L insulin was added. Subsequently, levels of AKT and phos-
phorylated AKT were measured and quantiﬁed as described earlier. There are
three NF-kB (RelA) siRNA sequences in the kit. They are as follows: CCAU-
CAACUAUGAUGAGUUtt, CCGGAUUGAGGAGAAACGUtt, and GCCCAUG-
GAAUUCCAGUACtt.
RelA mRNA expression assessment: RT-PCR. Expression of NF-kB (RelA)
mRNA was assessed by RT-PCR to gauge efﬁcacy of silencing (25–27) as
previously described. RNA was extracted using RNAwiz (Ambion, Austin, TX)
and further puriﬁed using a Dnase treatment and removal kit (Ambion, Austin,
TX). Gene-speciﬁc relative RT-PCR kits for rat NF-kB (Ambion) were used.
Gene and species-speciﬁc sense and antisense primers as provided by the
manufacturer were used. PCR products were resolved on an acrylamide gel,
silver stained, and relatively quantiﬁed using 18S ribosomal RNA as endoge-
nous control.
Assessment of RelA protein and modiﬁed EPCs. EPCs were cultured as
described above, and RelA protein levels were measured using 10 nmol/L, 20
nmol/L, and 30 nmol/L concentrations of the RelA siRNA combination (ID1 and
ID2). EPCs were transfected with RELA siRNA (Applied Biosystems). Cells
were allowed to grow for 48 h. Cells were ﬁxed with 4% formaldehyde and an
in-cell Western assay was performed as per Li-Cor’s instructions using RELA
primary antibody (Cell Signaling) and DRAQ5 and Sapphire700 dyes (Li-Cor)
for normalization. Protein levels of RelA are shown as percent of control
levels. Modiﬁed EPCs were then assessed for TNF-a–induced IL-8 secretion
and the effect of TNF-a on insulin signaling and apoptosis as described above.
Third set of experiments. In this experiment, all groups of Zucker fatty rats
underwent carotid angioplasty as described below. There were four groups of
rats with four rats in each group (total n = 16). Group 1 served as untreated
controls. Group 2 rats were given unmodiﬁed Zucker rat CD45,133,34 EPCs
(13 10
6 cells) postangioplasty intra-arterially. Group 3 rats were given Zucker
rat CD45,133,34 EPCs (13 10
6 cells) modiﬁed to knockdown RelA with
SureStep shRNA plasmids as described below (postangioplasty intra-arterially).
For these three groups, carotids were harvested 3 weeks postangioplasty and
neointimal hyperplasia was measured as described below. Group 4 rats were
given modiﬁed Zucker rat CD45,133,34 EPCs, which were further labeled with
the Qtracker system. The purpose of this group was to track and see whether
modiﬁed EPCs were able to migrate, adhere, and proliferate in the injured areas
of the carotid. The carotids for this group were harvested at 48 h (n =2 )a n d
1w e e k( n =2 )p o s t a n g i o p l a s t y .
SureSilencing shRNA plasmid transfection: EPC modiﬁcation. Zucker
rat EPCs were obtained, expanded, and sorted as described above. They were
then modiﬁed as follows. SureSilencing shRNA plasmids (SABiosciences) for
NF-kB were used to ensure long-term stable transfection. One day before
transfection, 8 3 10
6 cells were seeded in each well of a 24-well plate (for
roughly 30–35% conﬂuence) with 400 mL growth medium. On the day of
transfection, 0.40 mg of each gene-speciﬁc shRNA plasmid and the negative
control shRNA plasmid were added into separate 50-mL aliquots of Opti-
MEM I Reduced-Serum Medium (Gibco). SureFECT (3.0 mL) was added
to 50 mLO p t i - M E M( 7 . 5mL SureFECT per microgram of plasmid) in each
well. This was incubated for 10 min at room temperature. Then 50 mLo f
SureFECT was added to each 50 mL shRNA mix and incubated for 20 min
at room temperature. Thereafter, each 100 mL mixture of shRNA and
SureFECT was added to the appropriate well containing cells and 400 mL
normal growth medium. Cells were incubated at 37°C in a CO2 incubator for
24–48 h. Subsequently, the transfection efﬁciency as the number of transfected
cells divided by the total number of cells was determined by RT-PCR as de-
scribed above.
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balanced salt solution (Lonza) and then detached with trypsin (Lonza) and
neutralized with TNS (Lonza). Cells were centrifuged to pellet cells and
then resuspended and counted. Qtracker Component A and Component B
(Invitrogen) were mixed in a 15-mL sterile conical tube and incubated for
5 min. Complete endothelial growth medium-2 (Lonza) was added to conical
tubes and mixed. EPCs were added to the tubes and incubated at 37°C for
60 min. The cells were washed twice with sterile saline. Cells were visualized
on the Odyssey (Li-cor) to check labeling of cells. Cells were held on ice until
they were ready for injection.
Carotid angioplasty. Zucker fa/fa obese rats (age 14–15 weeks) were used.
Angioplasty was done using a modiﬁed version of a method that has been used
by us before (28,29). Rats were anesthetized with isoﬂourane, and the inner
left thigh was shaved and cleaned. Under aseptic conditions, an incision was
made to expose the left femoral artery. Homeostasis was achieved with an
arterial clamp. A 2.3-F, 2-mm, balloon-length (20 mm) percutaneous trans-
luminal coronary angioplasty catheter (Boston SCI-Med) was introduced into
the femoral artery. The catheter was directed to the left carotid artery, with
the help of a guide wire, under ﬂuoroscopic guidance. Angioplasty was done at
4 atmospheres (atm), and then pressure was reduced to 2 atm and the balloon
was dragged down the entire carotid from its bifurcation to the aortic arch as
done in previous experiments. The balloon was then deﬂated. EPCs either
unmodiﬁed or modiﬁed (1 3 10
6) were then given intra-arterially over 10 min,
and the catheter removed. The femoral artery was ligated and homeostasis
achieved. The wound was closed in three layers. Skin staples were used. Rats
were under direct close observation for the next 30 min. All procedures were
performed under a dissecting microscope and in the setting of a sterile vivarial
operating room. When this procedure is used, neointimal thickness is de-
tectable within 1 week and is extensive by 3 weeks.
Tissue retrieval. Rats were killed with carbon dioxide. Carotid arteries were
perfused with formalin prior to removal. Through a midline cervical incision,
both the left and the right carotid, from the aortic arch to the bifurcation, were
removed and preserved in formalin.
Tracking of exogenously delivered modiﬁed EPCs. The rat carotids were
perfused with PBS followed by 4% paraformaldehyde. The aortic arch and
carotidswereremovedfromtheratandputinparaformaldehydeand,later,70%
alcohol. The carotids were slit open and placed on a slide. The slide was
scanned on the Odyssey (Li-cor) by scanning for the 800 nm ﬂuorescence. The
Qtracker 800 (Invitrogen) will ﬂuoresce at 800 nm while the carotid will not
ﬂuoresce. The Qtracker is inherited for at least six generations of daughter
cells, providing a relatively long-term retention in cells.
Localization of modiﬁed EPCs in the injured carotid. An injured carotid
section was taken 1 week postangioplasty and DAPI, and Q-tracker 800 double
stainingwasvisualizedunderhighresolution.DAPIdyewasdiluted1:2,000,and
tissues were exposed to the dye for 5 min. The tissues or cells were put on
a slide and coverslip and viewed under a microscope. EPCs, double staining
with Q-Tracker (red) and nuclear staining (blue), were visualized.
CD45,133,34 characterization of modiﬁed EPCs in vitro and in vivo.
The rat modiﬁed primary EPCs were plated on poly-L-Lysine–coated slides and
preserved with formalin. The cells were blocked with 5% BSA in PBS, and
the appropriate primary antibodies—CD133, phycoethrin conjugated (eBio-
science); CD133, phycoethrin-Cy7 conjugated (Santa Cruz); and CD45, AF647
conjugated (BioLegend)—were diluted and incubated with the cells. The cells
were rinsed with PBS and mounted with Fluoromount-G (Southern Biotech).
The samples were taken to the Confocal Laser Scanning Microscope Core
Facility and analyzed on the Zeiss 510 Meta Confocal Laser Scanning Micro-
scope using the 403 optic for the modiﬁed EPCs.
CD45,133,34 characterization of modiﬁed EPCs in vivo. Modiﬁed EPCs
were given to Zucker rats postangioplasty as describedabove, andcarotids were
harvested at 48 h. The carotid was prepared and preserved with formalin and
then blocked with 5% BSA in PBS, and the appropriate primary antibodies—
CD133, phycoethrin conjugated (eBioscience); CD133, phycoethrin-Cy7 con-
jugated (Santa Cruz); and CD45, AF647 conjugated (BioLegend)—were diluted
and incubated with the carotid. The cells were rinsed with PBS, and the
carotid was mounted with Fluoromount-G (Southern Biotech). The samples
were taken to the Confocal Laser Scanning Microscope Core Facility and
analyzed on the Zeiss 510 Meta Confocal Laser Scanning Microscope using the
203 optic for the carotid.
Morphometric analysis: evaluation of neointimal hyperplasia. Mor-
phometric analysis was done using a previously described method (28,29). The
left carotid from the junction of the aortic arch to the junction of the bi-
furcation was taken. Formaldehyde-ﬁxed carotids were embedded in parafﬁn.
The carotid was sectioned into four equal parts. Four sections from the two
middle parts at 3-mm intervals were used for analysis. The neoinitimal hy-
perplasia is maximal in the middle of the vessel as endothelial regrowth occurs
from the aortic root and from the bifurcation and is last to regrow in this area.
All four sections, as described above, were selected for measurements. Sec-
tions were stained with hematoxylin. Analysis on the stained sections was
done with 310 microscopic magniﬁcation. Computerized digital microscopic
software (An@lysis) was used to obtain measurements of the intimal and
medial areas by a previously described method (30). The I/M ratio was then
obtained.
Statistical analysis. All statistical analysis were done using Prizm software
(Graphpad, San Diego, CA). For the in vitro experiments, statistical analysis
was performed on at least ﬁve independent observations in each experimental
set by one-way ANOVA or Student t test according to the experimental design.
If the overall ANOVA P value was signiﬁcant, pairwise multiple comparisons
were performed by a Student-Newman-Keuls test or the Tukey test. The
results are expressed as means 6 SEM. The threshold for statistical signiﬁ-
cance was set as P , 0.05.
For the animal experiments, the statistical data analysis was a two-way
ANOVA, with factors being treatment (three groups). If ANOVA was signiﬁcant,
we followed up with a Tukey post hoc test to identify which subgroups were
different. The overall level of signiﬁcance was kept at 0.05.
FIG. 1. A: Zucker rat EPCs exposed to TNF-a showed a marked 56% reduction in insulin (Ins)-stimulated AKT phosphorylation (phospho). Ad-
dition of NF-kB inhibitor BAY11 improved insulin-stimulated AKT phosphorylation in the presence of TNF-a to 80% of the insulin-stimulated AKT.
B: SD rat EPCs exposed to TNF-a showed a marked 61% reduction in insulin-stimulated AKT phosphorylation. Addition of NF-kB inhibitor BAY11
improved insulin-stimulated AKT phosphorylation in the presence of TNF-a to 97% of the insulin-stimulated AKT.
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First set of experiments
Insulin signaling. EPCs obtained from Zucker fatty rats
were much more resistant to insulin as measured by Akt
phosphorylation when compared with SD rats at various
escalating doses of insulin. This suggests that EPCs from
Zucker fatty rats are insulin resistant (Supplementary Fig. 1).
EPCs obtained from Zucker Fatty rats were treated with
different doses of TNF-a to obtain a dose-response curve
for TNF-a–stimulated IL-8, and the ideal determined TNF-a
dose was 10 ng/mL (Supplementary Fig. 2).
Zucker EPCs exposed to TNF-a showed a marked
56% reduction in insulin-stimulated AKT phosphorylation
(Fig. 1A). Addition of NF-kB inhibitor BAY11 improved
insulin-stimulated AKT phosphorylation in the presence
of TNF-a to 80% of the insulin alone–stimulated AKT
(Fig. 1A). SD rat EPCs exposed to TNF-a showed a
marked 61% reduction in insulin-stimulated AKT phos-
phorylation (Fig. 1B). Addition of NF-kB inhibitor BAY11
improved insulin-stimulated AKT phosphorylation in the
presence of TNF-a to 97% of the insulin-stimulated AKT
(Fig. 1B). This suggests that insulin signaling in both
Zucker and SD rat EPCs can be disrupted by cytokines and
the inhibition of NFKB will reverse some of this signaling
defect. In SD rat EPCs, the baseline stimulation of Akt is
much higher than in Zucker EPCs. SD rat EPCs have a
reduction in Akt phosphorylation similar to that of Zucker
EPCs; however, BAY11, the NF-kB inhibitor, is fully able to
reverse this defect in SD EPCs but only partially reverses it
in Zucker EPCs.
Apoptosis. TNF-a increased apoptosis in EPCs signiﬁ-
cantly (71%) compared with controls. Addition of the NF-
kB inhibitor BAY11 decreased apoptosis down to control
levels (Fig. 2). Transferase-mediated dUTP nick-end la-
beling assay further conﬁrmed this (Supplementary Fig. 4).
Reduction of apoptosis could lead to increase survival
time and, therefore, increased number of EPCs.
Second set of experiments
Reduction of NF-kB( R e l A )m R N Ae x p r e s s i o ni n
cultured Zucker EPCs. EPCs were transfected with
siRNA initially for glyceraldehyde-3-phosphate dehydro-
genase to verify whether EPCs are amenable to transfection
as described in RESEARCH DESIGN AND METHODS. Glyceraldehyde-
3-phosphate dehydrogenase expression was measured by
FIG. 2. Effect of TNF-a on apoptosis and reversal by NF-kB inhibitor
BAY11 (Zucker rat EPCs). TNF-a increased apoptosis in EPCs signiﬁ-
cantly (71%) compared with controls. Addition of the NF-kB inhibitor
BAY11 (BAY) decreased apoptosis down to control levels. #P < 0.05 vs.
control and TNF-a plus BAY11.
FIG. 3. A: siRNA knockdown of NF-kB. Each of the individual RelA siRNAs was able to decrease RelA mRNA expression as measured by RT-PCR.
siRNA no. 1 had greatest effect, with a 63% decrease. siRNA no.3 was not effective (not shown). Combination of both RelA siRNAs resulted in a
71% reduction in NF-kB (RelA) mRNA expression. B: Protein knockdown of RelA using siRNA. RelA protein levels were measured using 10 nmol/L,
20 nmol/L, and 30 nmol/L concentrations of the RelA siRNA combination (ID1 and ID2). There was a 60, 70, and 59% decrease in RelA protein with
the various concentrations, respectively, which matches the decreases seen in mRNA expression.
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(88%) (Supplementary Fig. 3).
EPCs were then transfected with three different siRNAs
for RelA separately and in combination. These were
obtained from Ambion, as described in RESEARCH DESIGN AND
METHODS. Each of the individual RelA siRNAs was able to
decrease RelA expression as measured by RT-PCR. siRNA
no. 1 had greatest effect with a 63% decrease (Fig. 3).
siRNA no.3 was not effective (not shown). Combination of
both RelA siRNAs resulted in a 71% reduction in NF-kB
(RelA) expression (Fig. 3A). This suggests that RelA mRNA
expression is signiﬁcantly reduced in these modiﬁed Zucker
rat EPCs.
Reduction of NF-kB (RelA) protein in cultured Zucker
EPCs. To further conﬁrm that the decrease in RelA mRNA
expression results in actual decrease in the RelA protein,
in-cell Western measurements showed a 60, 70, and 59%
decrease in RelA protein with the 10, 20, and 30 nmol/L
concentrations, respectively, which matches the decreases
seen in mRNA expression (Fig. 3B).
Suppression of TNF-a–stimulated IL-8 production in
NF-kB (RelA) knockdown EPCs. EPCs in which RelA
was suppressed as described above were exposed to
10 ng/mL TNF-a and compared with control nonaltered
EPCs. The TNF-a–stimulated IL-8 production in the NF-kB
suppressed cells was 46% less than that of the control
nonsense siRNA EPCs (Fig. 4). This shows that RelA-
suppressed EPCs are more resistant to an inﬂammatory
stimulus such as TNF-a. These EPCs may therefore func-
tion better in an inﬂammatory environment.
Improved insulin signaling in TNF-a–exposed, NF-kB
(RelA) knockdown EPCs. EPCs in which RelA was sup-
pressed were exposed to 10 ng/mL TNF-a as described in
RESEARCH DESIGN AND METHODS and compared with control
nonaltered EPCs (Fig. 7). Modiﬁed EPCs exposed to TNF-a
showed a lesser reduction (20%) in insulin-stimulated AKT
phosphorylation versus a 55% reduction in unmodiﬁed
EPCs (Fig. 5). This shows that insulin signaling is im-
proved in RelA-suppressed EPCs compared with unmod-
iﬁed EPCs in an inﬂammatory environment. Improved
insulin signaling could lead to better functioning and,
hence, improved healing postangioplasty.
Decreased apoptosis in TNF-a–exposed NF-kB( R e l A )
knockdown EPCs. EPCs in which RelA was suppressed
as described above were exposed to 10 ng/mL TNF-a and
compared with control nonaltered EPCs (Fig. 6). Modiﬁed
EPCs exposed to TNF-a showed a lesser degree of apo-
ptosis compared with unmodiﬁed control EPCs (41% de-
crease for RelA knockdown) (Fig. 6).
Third set of experiments
Decreased neointimal hyperplasia postangioplasty
in rats receiving modiﬁed EPCs. Zucker rats under-
went carotid angioplasty as described in RESEARCH DESIGN
AND METHODS. Three groups of rats were assessed for neo-
intimal hyperplasia postangioplasty. Group 1 served as
untreated controls, and group 2 rats were given unmodiﬁed
Zucker rat CD45,133,34 EPCs (13 10
6 cells) postangioplasty
intra-arterially. Group 3 rats were given Zucker rat
CD45,133,34 EPCs (13 10
6 cells) modiﬁed to knockdown
NF-kB with SureStep silencing RNA plasmids as described
above: postangioplasty intra-arterially. Carotids were har-
vested 3 weeks postangioplasty.
There was a 32% reduction in carotid intimal hyperplasia
in the Zucker rats treated with unmodiﬁed EPCs versus
untreated controls (I/M ratio 1.02 vs. 1.62, respectively)
(Fig. 7A and B). There was a 64% reduction in carotid
intimal hyperplasia in Zucker rats treated with NF-kB–
suppressed and modiﬁed EPCs versus that in untreated
controls (I/M ratio 0.58 vs. 1.62, respectively) (Fig. 7A and B).
These data clearly support the use of modiﬁed CD45,133,34
EPCs in reducing intimal hyperplasia.
The fourth group of rats also underwent angioplasty and
received modiﬁed EPCs. However, they were killed at 48 h
and 1 week to track the modiﬁed EPCs postangioplasty
FIG. 5. Effect of NF-kB (RelA) knockdown on AKT phosphorylation in
Zucker EPCs. Zucker rat EPCs in which RelA was suppressed as de-
scribed above were exposed to 10 ng/mL TNF-a and compared with
control nonaltered EPCs. Modiﬁed EPCs exposed to TNF-a showed
a lesser reduction (20% decrease) in insulin (Ins)-stimulated AKT
phosphorylation vs. a 55% reduction in unmodiﬁed EPCs. This shows
that insulin signaling is improved in RelA-suppressed EPCs compared
with unmodiﬁed EPCs in an inﬂammatory environment. @P < 0.05 vs.
nonsense siRNA plus TNF plus insulin.
FIG. 4. Suppression of TNF-a–stimulated IL-8 production in NF-kB
knockdown EPCs. Zucker rat EPCs, in which RelA was suppressed, were
exposed to 10 ng/mL TNF-a and compared with control nonaltered EPCs.
The TNF-a–stimulated IL-8 production in the NF-kB–suppressed cells
was 46% less than that of the control nonsense siRNA EPCs. This shows
that RelA-suppressed EPCs are more resistant to an inﬂammatory stim-
ulus such as TNF-a.# P < 0.05 vs. nonsense siRNA and blank plus TNF.
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to the injured areas (red ﬂuorescence) to a small extent
48 h later (Fig. 8A). EPCs proliferated and were more
abundant 1 week later (Fig. 8A). An injured carotid section
was taken 1 week postangioplasty, and DAPI and Q-tracker
800 double staining was visualized under high resolution.
EPC double staining with Q-Tracker (red) and nuclear
staining (blue) can be clearly seen (arrows) amid other
cells with nuclear stain only (Fig. 8B). EPCs were fur-
ther identiﬁed for CD 45,133,34 staining in vivo to ensure
that EPCs had not yet changed characteristics (Fig. 8C).
EPCs can be characterized as early, late, or circulating
depending on the CD markers identiﬁed. The question of
which set of CD markers deﬁne which set of functional
characteristics is still being sorted out. We refer the reader
to an excellent review on this topic (31). This experiment
shows that the modiﬁed EPCs can be tracked through
initial cycles of proliferation at the site of vascular injury.
DISCUSSION
Several of the abnormalities associated with insulin resis-
tance, including reduced nitric oxide (NO) bioavailability,
increased production of reactive oxygen species, and
downregulation of intracellular signaling pathways, have
the potential to disrupt EPC function. Improvement in the
number and function of EPCs may contribute to the
protective actions of evidence-based therapies to reduce
cardiometabolic risk (32). In this study, we show that
EPCs from an insulin-resistant rat model, Zucker fatty rats,
have impaired insulin signaling when exposed to an in-
ﬂammatory stimulus. When EPCs from Zucker fatty rats
were exposed to a cytokine, TNF-a, the insulin signaling
defect as measured by AKT phosphorylation was wors-
ened. EPCs also had increased apoptosis. By contrast,
there is some evidence suggesting that NF-kB is involved
in preventing TNF-a–induced apoptosis (12,33); however,
in our study NF-kB suppression resulted in decreased
apoptosis. In EPCs, the PI3K/Akt pathway has been im-
plicated in the mobilization of EPCs from the bone mar-
row, EPC differentiation, and inhibition of EPC apoptosis.
FIG. 7. A: Zucker fatty rat uninjured right carotid (top left), Zucker fatty rat untreated control injured carotid showing marked intimal hyperplasia
(top right), Zucker fatty rat carotid treated with unmodiﬁed Zucker rat EPCs showing decreased carotid intimal hyperplasia (bottom left), and
Zucker fatty rat carotid treated with modiﬁed Zucker rat EPCs showing markedly decreased carotid intimal hyperplasia (bottom right).
B: Quantiﬁcation of neointimal hyperplasia. There was a 64% reduction in carotid intimal hyperplasia in Zucker rats treated with NF-kB–sup-
pressed modiﬁed EPCs vs. untreated controls (I/M ratio 0.58 vs. 1.62, respectively). (A high-quality color representation of this ﬁgure is available
in the online issue.)
FIG. 6. Effect of RelA knockdown on apoptosis in Zucker fatty EPCs.
Zucker rat EPCs in which RelA was suppressed were exposed to 10 ng/mL
TNF-a and compared with control nonaltered EPCs. Modiﬁed EPCs ex-
posed to TNF-a showed a lesser degree of apoptosis compared with un-
modiﬁed EPCs (41% decrease for RelA knockdown).
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tion in response to statins and pioglitazone (34,35). Statins
induce EPC differentiation via the PI3K/Akt pathway, as
demonstrated by the inhibitory effect of selective pharma-
cological inhibitors (34). Genetic deletion of Akt1 in mice
results in impaired mobilization of EPCs in response to
both ischemia and vascular endothelial growth factor (36).
Downregulation of insulin signaling in insulin-resistant
animals is selective for the PI3K/Akt pathway while signal
transduction via the MAPK pathway is maintained (37).
Selective abnormalities of PI3K/Akt signaling, therefore,
may link insulin resistance with defective EPC survival,
mobilization, proliferation, differentiation, and apoptosis.
In this study, we have shown that inﬂammatory cytokines
are likely to disrupt EPC insulin signaling and increase
EPC apoptosis. Strategies that alleviate this disruption of
FIG. 8. A: Modiﬁed EPCs were labeled with Q-tracker 800 and given to rats just after angioplasty at the injury site as described in RESEARCH DESIGN
AND METHODS. Carotids were harvested 48 h and 1 week later and visualized using Odyssey (Li-cor) to check labeling of cells. A: The right carotid
served as control (top), EPCs were detected adherent to the injured areas (red ﬂuorescence) to a small extent 48 h later (center), and EPCs
proliferated and were much more abundant 1 week later (bottom). This experiment shows that the modiﬁed EPCs can be tracked initially and after
several cycles of proliferation at the site of vascular injury. B: An injured carotid section was taken 1 week postangioplasty, and DAPI and
Q-tracker 800 double staining were visualized under high resolution. EPCs double staining with Q-Tracker (red) and nuclear staining (blue) can be
clearly seen (arrows) amid other cell with nuclear stain only. C: An injured carotid section was taken out 48 h after angioplasty, and EPCs sating
with CD45,133 were identiﬁed adherent to the carotid surface. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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survival and function.
Some studies suggest that inhibitory effects on insulin
signaling may be mediated by NF-kB, c-jun NH2-terminal
kinase, or MAPK pathways (38–41); hence, the inability
of EPCs to respond adequately to insulin may result in
dysfunction in the setting of insulin-resistant states. More-
over, insulin has potent anti-inﬂammatory effects that are
greatly decreased as a result of the insulin resistance (42).
This further increases inﬂammation, creating a pathologi-
cal loop. We have demonstrated for the ﬁrst time that
inhibiting this pathological loop by knocking down NF-kB
(RelA) and thus modifying Zucker rat EPCs can lead to
improved insulin signaling and increased EPC survival.
Most importantly, improvement in EPC insulin signaling
and survival should ultimately lead to improved vascular
outcomes in in vivo models. In our model of vascular in-
jury and restenosis in Zucker fatty rats, we show for the
ﬁrst time that EPCs modiﬁed by a knockdown of NF-kB
(RelA), lead to decreased neointimal hyperplasia. Our
study shows that increasing the number of EPCs in cir-
culation is effective in decreasing neointimal hyperplasia
postangioplasty. However, modifying EPCs so as to block
the inﬂammatory stimulus leads to an even greater re-
duction in neointimal hyperplasia. EPCs resistant to cyto-
kine stimulation would have improved insulin signaling
and, hence, better function such as adhesion, migration,
and proliferation, thus increasing the efﬁcacy of reendo-
thelialization and inhibition of vascular smooth muscle
proliferation. We show in our study that these modiﬁed
EPCs migrate and adhere to the injured areas of the blood
vessel. It is possible that future studies show that they
proliferate within the newly forming endothelium. Further
studies need to be done to evaluate whether these modi-
ﬁed EPCs stimulate more rapid endothelial regrowth or
inhibit vascular smooth muscle proliferation.
In conclusion, we have shown that insulin signaling and
EPC survival are impaired in Zucker fatty insulin-resistant
rats. This defect can be ameliorated signiﬁcantly by
a knockdown of RelA. Modiﬁed EPCs then transfused into
an insulin-resistant rat model reduce neointimal hyper-
plasia. The potential for translating this to humans would
be very beneﬁcial to patients who are at risk for cardio-
vascular disease in the setting of insulin resistance and
inﬂammation.
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